Reading the tape
NASDAQ: MNKD
MannKind Corporation
Healthcare · Biotechnology
Market Cap
$884.70M
52w High
$6.51
52w Low
$2.23
P/E
148.84
Volume
2.05M
Outstanding Shares
308.80M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -42.44%Revenue (TTM): 22.23%FCF (TTM): -58.76%P/E: 78th pct
What changed
The stock fell 42.44% over the last year. Revenue grew 22.23% over the trailing twelve months. Operating margin moved from 25.42% to 11.08%. Free cash flow declined 58.76% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 11.08%. A decisive move in revenue — currently up 22.23% — would be the clearest signal to resolve the ambiguity.
Company profile
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States.
CEOMichael E. Castagna
SectorHealthcare
IndustryBiotechnology
Employees403
IPO dateJul 28, 2004
Valuation
Forward P/E—
EV/EBITDA77.45
Enterprise value$2.13B
Stock splits
Mar 3, 2017↓ Reverse
Every 5 shares became 1
Profitability & growth
Revenue growth45.82%
Gross margin76.39%▲12.72%vs FY2024
Operating margin11.08%▼56.27%vs FY2024
ROE-11.49%▲67.17%vs FY2024
Analyst consensus
RatingBuy
Target price$7.00▲144.33%
9
Buy
3
Hold
7
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 6, 2026
Q2 FY26 · EPS est -$0.02 · Revenue est $105.38M
View